Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197682796> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W3197682796 endingPage "340" @default.
- W3197682796 startingPage "339" @default.
- W3197682796 abstract "AR101, an investigational oral biologic drug for peanut oral immunotherapy, was studied in PALISADE and ARTEMIS phase 3 trials. Efficacy and safety are compared. Subjects demonstrated clinical history of peanut allergy; peanut-specific immunoglobulin E ≥ 0.35 kUA/L and/or skin-prick test ≥ 3 mm; reacted to ≤ 100 mg (PALISADE)/≤ 300 mg peanut protein (ARTEMIS) at screening double-blind, placebo-controlled food challenge (DBPCFC). After dose escalation to 300 mg/day (6 months), 300 mg/day dosing continued (PALISADE, 6 months; ARTEMIS, 3 months). Results are reported in subjects 4-17-years-old (intention-to-treat/safety populations). A total of 496 PALISADE (AR101 n = 372, placebo n = 124) and 175 ARTEMIS ( n = 132, n = 43) subjects were treated. Ability to tolerate 300 mg, 600 mg or 1000 mg peanut protein at exit DBPCFC was similar (PALISADE vs ARTEMIS; AR101 : 76.6% vs 73.5%, 67.2% vs 68.2%, 50.3% vs 58.3%; placebo : 8.1% vs 16.3%, 4.0% vs 9.3%, 2.4% vs 2.3%). Most treatment-emergent adverse events (TEAEs) were mild/moderate (AR101, placebo : PALISADE 94.4%, 94.4%; ARTEMIS 97.7%, 97.7%); frequency decreased from dose-escalation to 300 mg/day dosing (X). For dose-escalation in-clinic TEAEs, range of median times to symptom onset following ingestion and times from first symptom onset to last symptom resolution were similar (AR101, placebo: PALISADE onset 4.0–5.5 min, 8.0–38.5 min; resolution 16.0–32.5 min, 15.0–38.0 min; ARTEMIS onset 2.0–10.0 min, 1.5–15.0 min; resolution 14.0–47.8 min, 7.0–85.0 min) ( Fig. 1 ). AR101 efficacy and safety results are consistent across trials despite different entry criteria. Most TEAEs were mild/moderate and transient. AR101 has a readily manageable safety profile with high desensitization rates possible as early as 3 months after 300 mg/day dosing." @default.
- W3197682796 created "2021-09-13" @default.
- W3197682796 creator A5004324665 @default.
- W3197682796 creator A5005858957 @default.
- W3197682796 creator A5008227815 @default.
- W3197682796 creator A5013221361 @default.
- W3197682796 creator A5024276008 @default.
- W3197682796 creator A5038345058 @default.
- W3197682796 creator A5042524053 @default.
- W3197682796 creator A5063252980 @default.
- W3197682796 creator A5070186406 @default.
- W3197682796 creator A5074257666 @default.
- W3197682796 creator A5076837032 @default.
- W3197682796 date "2021-09-01" @default.
- W3197682796 modified "2023-09-30" @default.
- W3197682796 title "Safety and efficacy comparison : ARTEMIS and PALISADE phase 3 studies of AR101 in peanut allergy" @default.
- W3197682796 doi "https://doi.org/10.1016/j.reval.2020.09.009" @default.
- W3197682796 hasPublicationYear "2021" @default.
- W3197682796 type Work @default.
- W3197682796 sameAs 3197682796 @default.
- W3197682796 citedByCount "0" @default.
- W3197682796 crossrefType "journal-article" @default.
- W3197682796 hasAuthorship W3197682796A5004324665 @default.
- W3197682796 hasAuthorship W3197682796A5005858957 @default.
- W3197682796 hasAuthorship W3197682796A5008227815 @default.
- W3197682796 hasAuthorship W3197682796A5013221361 @default.
- W3197682796 hasAuthorship W3197682796A5024276008 @default.
- W3197682796 hasAuthorship W3197682796A5038345058 @default.
- W3197682796 hasAuthorship W3197682796A5042524053 @default.
- W3197682796 hasAuthorship W3197682796A5063252980 @default.
- W3197682796 hasAuthorship W3197682796A5070186406 @default.
- W3197682796 hasAuthorship W3197682796A5074257666 @default.
- W3197682796 hasAuthorship W3197682796A5076837032 @default.
- W3197682796 hasConcept C126322002 @default.
- W3197682796 hasConcept C142724271 @default.
- W3197682796 hasConcept C197934379 @default.
- W3197682796 hasConcept C203014093 @default.
- W3197682796 hasConcept C204787440 @default.
- W3197682796 hasConcept C207480886 @default.
- W3197682796 hasConcept C27081682 @default.
- W3197682796 hasConcept C2776027960 @default.
- W3197682796 hasConcept C2777288759 @default.
- W3197682796 hasConcept C2778012357 @default.
- W3197682796 hasConcept C71924100 @default.
- W3197682796 hasConceptScore W3197682796C126322002 @default.
- W3197682796 hasConceptScore W3197682796C142724271 @default.
- W3197682796 hasConceptScore W3197682796C197934379 @default.
- W3197682796 hasConceptScore W3197682796C203014093 @default.
- W3197682796 hasConceptScore W3197682796C204787440 @default.
- W3197682796 hasConceptScore W3197682796C207480886 @default.
- W3197682796 hasConceptScore W3197682796C27081682 @default.
- W3197682796 hasConceptScore W3197682796C2776027960 @default.
- W3197682796 hasConceptScore W3197682796C2777288759 @default.
- W3197682796 hasConceptScore W3197682796C2778012357 @default.
- W3197682796 hasConceptScore W3197682796C71924100 @default.
- W3197682796 hasFunder F4320306194 @default.
- W3197682796 hasFunder F4320309075 @default.
- W3197682796 hasFunder F4320332161 @default.
- W3197682796 hasIssue "5" @default.
- W3197682796 hasLocation W31976827961 @default.
- W3197682796 hasOpenAccess W3197682796 @default.
- W3197682796 hasPrimaryLocation W31976827961 @default.
- W3197682796 hasRelatedWork W10326990 @default.
- W3197682796 hasRelatedWork W11437557 @default.
- W3197682796 hasRelatedWork W15367883 @default.
- W3197682796 hasRelatedWork W16927856 @default.
- W3197682796 hasRelatedWork W17424473 @default.
- W3197682796 hasRelatedWork W19828412 @default.
- W3197682796 hasRelatedWork W3090854 @default.
- W3197682796 hasRelatedWork W3197746 @default.
- W3197682796 hasRelatedWork W5548006 @default.
- W3197682796 hasRelatedWork W6918129 @default.
- W3197682796 hasVolume "61" @default.
- W3197682796 isParatext "false" @default.
- W3197682796 isRetracted "false" @default.
- W3197682796 magId "3197682796" @default.
- W3197682796 workType "article" @default.